Moricizine and quality of life in the Cardiac Arrhythmia Suppression Trial II (CAST II).

Abstract

The Cardiac Arrhythmia Suppression Trial II (CAST II) was a double-masked placebo-controlled randomized trial that compared the survival effects of moricizine to placebo in postmyocardial infarction arrhythmia patients. The quality-of-life outcome measures were designed prospectively for CAST and were previously shown to have high reliability and clinical discriminative validity. The CAST quality-of-life instrument detected significant differences between moricizine and placebo. In particular, moricizine was most strongly associated with inferior social activity and satisfaction scores (p = .014) and lower scores for overall contentment with life (p = .007). Moreover, the quality-of-life measures improved significantly for both the moricizine and placebo treatment groups after entry into the clinical trial. These results indicate that the CAST quality-of-life instrument is sensitive for assessing pharmacological therapies in the treatment of heart disease.

• Authors: M M Brooks, L Gorkin, E B Schron, I Wiklund, J Campion, R B Ledingham
• Journal: Controlled clinical trials (Control Clin Trials) Vol. 15 Issue 6 Pg. 437-49 (Dec 1994) ISSN: 0197-2456 [Print] United States
• PMID: 7851106 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Placebos
• Moricizine

Topics

• Aged
• Arrhythmias, Cardiac (drug therapy, physiopathology)
• Female
• Heart Ventricles (physiopathology)
• Humans
• Male
• Middle Aged
• Moricizine (adverse effects, therapeutic use)
• Placebo Effect
• Placebos
• Prospective Studies
• Quality of Life
• Surveys and Questionnaires
• Treatment Outcome